Last fall, SCDAA and the sickle cell disease (SCD) community issued a public petition to the White House, requesting reauthorization of the Sickle Cell Treatment Act, declaration of SCD as a national priority and funding for SCD programs in the President's budget. Recently the petition's success came into fruition by means of a direct response.
SCDAA has been designated to serve as the National Backbone Organization for the HRSA Sickle Cell Disease Newborn Screening Program. As the national backbone organization SCDAA will work with community-based organizations across the country to implement a strengthened approach to care, collective impact and strategic activities within the Sickle Cell community.
Our 43rd Annual Convention will take place September 23 - 26, 2015. Stay informed on all things convention related! Learn about this year's host hotel, events, announcements and abstract deadlines. Convention will be here before we know it!
Pfizer Inc. announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell...